US stock futures flounder amid tech weakness, Fed caution
IRVINE, Calif. - AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company, has announced its receipt of approval from the NYSE American LLC for a plan to regain compliance with the exchange’s listing standards. The NYSE American has granted AEON Biopharma until August 3, 2026, to meet the requirements concerning minimum market capitalization and stockholders’ equity as set forth in the NYSE American Company Guide. InvestingPro subscribers can track compliance-related metrics and receive real-time alerts on listing requirement status for AEON and other listed companies.
The compliance plan’s acceptance follows AEON’s efforts to address the exchange’s concerns regarding Sections 1003(a)(i), (ii), and (iii) of the Company Guide. AEON will undergo periodic reviews during this grace period to assess its progress towards meeting the outlined goals and initiatives. Failure to achieve compliance by the deadline or to demonstrate sufficient interim progress could result in delisting proceedings.
AEON specializes in developing its proprietary botulinum toxin complex, ABP-450, for various therapeutic indications, primarily within the neurosciences market. ABP-450, also marketed by Evolus under the name Jeuveau for cosmetic uses, is manufactured by Daewoong in compliance with current Good Manufacturing Practices. The product has received approval in several international markets, including Mexico and India, and AEON holds exclusive rights for its therapeutic use in key regions such as the United States, Canada, the European Union, and the United Kingdom. Gain deeper insights into the biotech sector and AEON’s market position with InvestingPro’s comprehensive analysis tools and peer comparison features.
The company’s management team boasts significant experience in biopharmaceutical development and botulinum toxin commercialization. AEON’s strategic efforts are focused on regaining compliance with the NYSE American listing standards within the designated Plan Period.
This announcement includes forward-looking statements regarding AEON’s ability to execute its compliance plan and the potential outcomes of its strategic initiatives. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.
Investors are reminded that this news is based on a press release statement from AEON Biopharma and should consider the company’s filings with the Securities and Exchange Commission for a comprehensive understanding of risks and uncertainties associated with AEON’s business. InvestingPro subscribers can access detailed risk assessment tools, financial health indicators, and expert analysis to make more informed investment decisions.
In other recent news, AEON Biopharma has announced a leadership change with the resignation of President and CEO Marc Forth, effective April 4, 2025. Jost Fischer, the Chairman of the Board, will serve as interim CEO while the company searches for a permanent replacement. In another development, AEON Biopharma’s Board of Directors has approved a 1-for-72 reverse stock split to meet NYSE American LLC compliance standards, effective February 26, 2025. This move is part of AEON’s strategy to maintain its stock listing by aligning with minimum share price requirements. The reverse stock split will not affect the ownership percentage of current stockholders, except for fractional shares, which will be adjusted accordingly. AEON continues to focus on developing its botulinum toxin complex, ABP-450, for therapeutic use, with ongoing plans for FDA discussions later in 2025. The company emphasizes that its cash reserves are adequate to support these upcoming regulatory engagements. AEON holds exclusive rights to develop and distribute ABP-450 for therapeutic purposes in several regions, including the United States and European Union. These recent developments are part of AEON Biopharma’s broader growth and compliance strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.